Drug Classification · Questions 1–6
Identify the pharmacological class or categorical label for each drug or receptor. Vocabulary preparation is sufficient to answer every question in this section.
Question 1
Which of the following drugs is classified as a selective estrogen receptor modulator?
Correct Answer
B — Clomiphene citrate
Rationale
Clomiphene citrate is classified as a selective estrogen receptor modulator. Like tamoxifen, raloxifene, and ospemifene, it produces tissue-selective effects at the estrogen receptor. Letrozole is an aromatase inhibitor, not a selective estrogen receptor modulator. Human menopausal gonadotropin is a urinary-derived gonadotropin preparation containing both follicle-stimulating hormone and luteinizing hormone activity. Leuprolide acetate is a gonadotropin-releasing hormone agonist.
Question 2
Which of the following drugs is classified as an aromatase inhibitor?
Correct Answer
D — Letrozole
Rationale
Letrozole is classified as an aromatase inhibitor. It blocks the aromatase enzyme (cytochrome P450 19A1), which converts androgens to estrogens in ovarian granulosa cells and peripheral tissues. Clomiphene citrate is a selective estrogen receptor modulator. Human chorionic gonadotropin is a chorionic gonadotropin used as a luteinizing hormone surrogate for ovulation triggering. Follitropin alfa is a recombinant follicle-stimulating hormone preparation.
Question 3
Which of the following gonadotropin preparations is classified as containing both follicle-stimulating hormone and luteinizing hormone activity?
Correct Answer
A — Human menopausal gonadotropin
Rationale
Human menopausal gonadotropin (menotropins) is extracted from the urine of postmenopausal women, which is rich in both follicle-stimulating hormone and luteinizing hormone because of the absence of negative feedback from the ovaries. The preparation retains both gonadotropin activities. Follitropin alfa and follitropin beta are recombinant follicle-stimulating hormone preparations containing only follicle-stimulating hormone activity. Urofollitropin is a highly purified urinary follicle-stimulating hormone preparation that also contains only follicle-stimulating hormone.
Question 4
Which of the following is classified as a recombinant follicle-stimulating hormone preparation?
Correct Answer
C — Follitropin alfa
Rationale
Follitropin alfa is classified as a recombinant follicle-stimulating hormone preparation. It is manufactured using recombinant deoxyribonucleic acid technology to produce highly consistent, defined-potency follicle-stimulating hormone without luteinizing hormone contamination. Urofollitropin is a highly purified follicle-stimulating hormone derived from postmenopausal urine, not produced by recombinant technology. Human menopausal gonadotropin is a urinary-derived preparation containing both follicle-stimulating hormone and luteinizing hormone. Human chorionic gonadotropin is a chorionic gonadotropin, not a follicle-stimulating hormone preparation.
Question 5
Which of the following is classified as a chorionic gonadotropin?
Correct Answer
A — Human chorionic gonadotropin
Rationale
Human chorionic gonadotropin is classified as a chorionic gonadotropin. It shares structural homology with luteinizing hormone — both share an identical alpha subunit and closely related beta subunits — and binds the luteinizing hormone receptor with high affinity. This is the basis for its use as a luteinizing hormone surrogate for ovulation triggering in assisted reproduction. Follitropin alfa is a recombinant follicle-stimulating hormone. Leuprolide acetate is a gonadotropin-releasing hormone agonist. Clomiphene citrate is a selective estrogen receptor modulator.
Question 6
Which of the following drugs is classified as a dopamine receptor agonist?
Correct Answer
C — Cabergoline
Rationale
Cabergoline is classified as a dopamine receptor agonist. It acts primarily at dopamine D2 receptors and is used clinically for hyperprolactinemia and Parkinson disease, and as adjunctive prophylaxis for ovarian hyperstimulation syndrome in assisted reproduction. Letrozole is an aromatase inhibitor. Human chorionic gonadotropin is a chorionic gonadotropin used as a luteinizing hormone surrogate. Follitropin alfa is a recombinant follicle-stimulating hormone preparation.
Core Pharmacology · Questions 7–14
Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.
Question 7
A woman with anovulation due to polycystic ovary syndrome is treated with clomiphene citrate. Which of the following best explains how this drug restores ovulation?
Correct Answer
B — Clomiphene blocks estrogen receptors in the hypothalamus, creating a perceived estrogen-deficient state that removes negative feedback and increases follicle-stimulating hormone secretion
Rationale
Clomiphene citrate is a selective estrogen receptor modulator that occupies estrogen receptor alpha in the hypothalamus. Under normal conditions, circulating estradiol binds these receptors and suppresses gonadotropin-releasing hormone pulsatility and pituitary follicle-stimulating hormone secretion through negative feedback. By blocking hypothalamic estrogen receptor alpha, clomiphene prevents estradiol from delivering its feedback signal. The hypothalamic-pituitary axis interprets this as an estrogen-deficient state and responds by increasing follicle-stimulating hormone secretion, which recruits and drives follicular development in women with intact axis function — particularly those with anovulation due to polycystic ovary syndrome.
Question 8
A physician explains to a patient taking clomiphene citrate that ovulation rates with this drug are high but pregnancy rates per cycle are lower than expected. Which of the following best explains this discrepancy?
Correct Answer
D — Clomiphene blocks estrogen receptors throughout the body, including in the endometrium and cervix, producing a thin poorly proliferating endometrium and viscous cervical mucus that impair implantation and sperm transport
Rationale
Clomiphene citrate presents a pharmacological paradox: the same hypothalamic estrogen receptor blockade that restores follicle-stimulating hormone and ovulation simultaneously impairs the peripheral uterine and cervical environment. The endometrium requires estradiol-driven proliferation for adequate thickness and receptivity; by blocking endometrial estrogen receptors, clomiphene produces a thin, poorly vascularized endometrium unsuitable for implantation. Cervical mucus permeability also depends on mid-cycle estrogen stimulation; clomiphene blocks cervical estrogen receptors, keeping mucus viscous and impenetrable to sperm. These combined anti-estrogenic peripheral effects mean the drug restores the egg but degrades the path to successful pregnancy, explaining why live birth rates per cycle are substantially lower than ovulation rates.
Question 9
Letrozole produces higher live birth rates than clomiphene citrate in women with polycystic ovary syndrome. Which of the following best explains this advantage?
Correct Answer
A — Letrozole transiently reduces estrogen production and then clears rapidly, allowing the developing follicle's own estradiol to act on an intact estrogen receptor throughout the uterus and cervix
Rationale
Letrozole inhibits aromatase in ovarian granulosa cells, transiently reducing estradiol production. This drop in estradiol removes negative feedback from the hypothalamic-pituitary axis, increasing follicle-stimulating hormone secretion and recruiting follicles — achieving the same initial result as clomiphene but by a different route. The key advantage is what happens next: letrozole has a short half-life and clears from the body before the developing follicle begins producing significant estradiol. Because letrozole works by inhibiting synthesis rather than blocking the receptor, estrogen receptors throughout the body remain free and intact. As follicular estradiol rises, it can act normally on the endometrium — producing good proliferation — and on cervical mucus — maintaining permeability. The result is a more physiological reproductive environment, higher live birth rates, and a lower rate of multiple gestation.
Question 10
A woman with hypogonadotropic hypogonadism (WHO Group I anovulation) begins treatment with recombinant follicle-stimulating hormone alone but shows inadequate follicular development. Which of the following best explains why follicle-stimulating hormone monotherapy is insufficient in this patient?
Correct Answer
C — In hypogonadotropic hypogonadism, absent luteinizing hormone means theca cells receive no stimulus to produce androgen precursors; without androgen substrate, granulosa cell aromatase cannot synthesize estradiol regardless of follicle-stimulating hormone levels
Rationale
Ovarian estradiol synthesis requires the cooperative action of two cell types as established by the two-cell, two-gonadotropin model. Luteinizing hormone stimulates theca cells to convert cholesterol to androgens (androstenedione and testosterone). Follicle-stimulating hormone then stimulates granulosa cells to express aromatase, which converts those theca-derived androgens into estrogens. In women with hypogonadotropic hypogonadism, both luteinizing hormone and follicle-stimulating hormone are absent. Providing follicle-stimulating hormone alone restores granulosa aromatase expression, but without luteinizing hormone to drive theca androgen production, there is no androgen substrate for aromatase to convert. Follicular development stalls because granulosa cells cannot synthesize estradiol without the theca-derived androgen precursors that only luteinizing hormone can generate. Treatment requires both gonadotropins: human menopausal gonadotropin, or recombinant follicle-stimulating hormone combined with recombinant luteinizing hormone.
Question 11
Human chorionic gonadotropin is used to trigger ovulation in assisted reproduction instead of native luteinizing hormone. Which of the following pharmacokinetic property of human chorionic gonadotropin also makes it the principal driver of ovarian hyperstimulation syndrome?
Correct Answer
B — Human chorionic gonadotropin has a half-life of 24 to 36 hours compared to approximately 60 minutes for native luteinizing hormone, producing prolonged luteinizing hormone receptor stimulation across multiple corpora lutea simultaneously
Rationale
Human chorionic gonadotropin and native luteinizing hormone both bind the luteinizing hormone receptor, but their pharmacokinetic profiles differ substantially. The half-life of a natural luteinizing hormone surge is approximately 60 minutes; the mid-cycle surge is brief and self-limiting. Human chorionic gonadotropin has a half-life of 24 to 36 hours due to differences in glycosylation that slow renal clearance. After an exogenous trigger injection, this prolonged half-life sustains luteinizing hormone receptor stimulation across multiple stimulated corpora lutea simultaneously — not just the single corpus luteum of a natural cycle. This sustained multi-corpora stimulation drives amplified vascular endothelial growth factor secretion for days, producing the capillary permeability cascade underlying ovarian hyperstimulation syndrome.
Question 12
A patient undergoing ovarian stimulation develops increasing abdominal distension, nausea, and oliguria 5 days after her trigger injection. Pelvic ultrasound shows markedly enlarged ovaries and substantial ascites. Which of the following best explains the physiological mechanism responsible for her ascites?
Correct Answer
D — Supraphysiological vascular endothelial growth factor from multiple stimulated corpora lutea increases capillary permeability, allowing protein-rich plasma to leak into the peritoneal cavity
Rationale
Supraphysiological vascular endothelial growth factor is produced by multiple stimulated corpora lutea and large pre-ovulatory follicles. Vascular endothelial growth factor binds receptors on peritoneal and ovarian capillary endothelium, dramatically increasing vascular permeability. Protein-rich plasma leaks out of capillaries into the peritoneal cavity, forming ascites. Because protein leaves with the fluid, the intravascular compartment loses oncotic pressure as well as volume, perpetuating the leak. The result is simultaneous third-space overload and intravascular hypovolemia — a state of hemoconcentration, reduced urine output, and in severe cases elevated thrombotic risk. This cycle continues as long as vascular endothelial growth factor production is sustained by ongoing luteinizing hormone receptor stimulation.
Question 13
In an antagonist-protocol ovarian stimulation cycle, a physician substitutes a gonadotropin-releasing hormone agonist for human chorionic gonadotropin as the ovulation trigger in a high-risk patient. Which of the following best explains how this substitution reduces ovarian hyperstimulation syndrome risk?
Correct Answer
A — The agonist stimulates a brief endogenous luteinizing hormone surge from the still-responsive pituitary; this surge is much shorter than the half-life of exogenous human chorionic gonadotropin, eliminating sustained luteinizing hormone receptor stimulation of multiple corpora lutea
Rationale
In antagonist-protocol cycles, the pituitary has not been downregulated and remains responsive to gonadotropin-releasing hormone stimulation. Administering a gonadotropin-releasing hormone agonist as the trigger stimulates an endogenous luteinizing hormone surge from the pituitary. This endogenous surge is short-lived — the pituitary rapidly downregulates in response to the agonist — lasting only a few hours compared to the 24 to 36 hours of persistent receptor stimulation produced by exogenous human chorionic gonadotropin. With brief rather than sustained luteinizing hormone receptor stimulation across multiple corpora lutea, the amplitude and duration of vascular endothelial growth factor secretion are dramatically reduced, eliminating severe ovarian hyperstimulation syndrome in virtually all high-risk patients. This approach is unavailable in long gonadotropin-releasing hormone agonist protocols because the pituitary has already been downregulated.
Question 14
A patient develops severe ovarian hyperstimulation syndrome after a fresh embryo transfer, with worsening ascites and hemoconcentration beginning on day 12 after her trigger injection. Her reproductive endocrinologist explains that this is late-onset ovarian hyperstimulation syndrome. Which of the following best explains why late-onset ovarian hyperstimulation syndrome tends to be more severe and prolonged than early-onset disease?
Correct Answer
C — The implanting embryo produces rising human chorionic gonadotropin that provides a continuous, escalating luteinizing hormone receptor stimulus to multiple corpora lutea, perpetuating vascular endothelial growth factor secretion beyond the window of exogenous trigger clearance
Rationale
Early-onset ovarian hyperstimulation syndrome is driven by the exogenous trigger injection — either human chorionic gonadotropin or the endogenous surge from a gonadotropin-releasing hormone agonist trigger — and typically resolves if pregnancy does not occur as the trigger hormone clears. Late-onset ovarian hyperstimulation syndrome begins around day 10 or more after the trigger and is driven by rising endogenous human chorionic gonadotropin secreted by the implanting embryo. Unlike the exogenous trigger, which clears within days, embryonic human chorionic gonadotropin rises continuously throughout the first trimester. This continuous, escalating stimulus to multiple corpora lutea sustains vascular endothelial growth factor secretion far longer than the exogenous trigger window, making late-onset disease more severe and prolonged. The freeze-all strategy — vitrifying all embryos and transferring in a subsequent unstimulated cycle — eliminates late-onset ovarian hyperstimulation syndrome entirely by preventing the embryonic human chorionic gonadotropin stimulus in the stimulated cycle.
Clinical Correlations · Questions 15–18
Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.
Question 15
A 32-year-old woman undergoing in vitro fertilization with a gonadotropin-releasing hormone antagonist protocol is considered high-risk for ovarian hyperstimulation syndrome based on her elevated anti-Mullerian hormone level. She receives human chorionic gonadotropin as her ovulation trigger. Her physician prescribes cabergoline starting on the day of trigger. Which of the following best explains how cabergoline reduces ovarian hyperstimulation syndrome risk in this patient?
Correct Answer
A — Cabergoline modulates vascular endothelial growth factor receptor-2 signaling on capillary endothelial cells, reducing the vascular permeability response to vascular endothelial growth factor without blocking vascular endothelial growth factor production itself
Rationale
Vascular endothelial growth factor drives ovarian hyperstimulation syndrome by binding to vascular endothelial growth factor receptor-2 on capillary endothelial cells, triggering a signaling cascade that dramatically increases capillary permeability. Cabergoline is a dopamine receptor agonist that modulates vascular endothelial growth factor receptor-2 signaling on endothelial cells through dopaminergic pathways, reducing the permeability response to vascular endothelial growth factor without blocking vascular endothelial growth factor production itself. The circulating vascular endothelial growth factor levels remain elevated, but the endothelial response is attenuated. Clinical data show that cabergoline reduces early ovarian hyperstimulation syndrome incidence in high-risk patients when used adjunctively. It does not eliminate the risk entirely, particularly for late-onset disease driven by embryonic human chorionic gonadotropin, which is why the freeze-all strategy remains the most effective prevention for high-risk patients.
Question 16
A 29-year-old woman undergoes her first in vitro fertilization cycle using a gonadotropin-releasing hormone antagonist protocol for pituitary suppression during ovarian stimulation. After oocyte retrieval, she has a fresh embryo transfer on day 5. Her physician prescribes daily vaginal progesterone starting on the day of retrieval and continuing through 10 weeks of gestation if pregnancy is confirmed. She asks why she needs progesterone supplementation when she just had multiple eggs retrieved and presumably has multiple active corpora lutea. Which of the following best explains why exogenous progesterone is required?
Correct Answer
C — Pituitary suppression by the gonadotropin-releasing hormone antagonist continues into the luteal phase, impairing the endogenous luteinizing hormone secretion that the multiple corpora lutea require to sustain progesterone production
Rationale
In a natural cycle, the corpus luteum is maintained in the early luteal phase by a pulse of luteinizing hormone from a pituitary that is fully responsive and active. In an in vitro fertilization cycle using a gonadotropin-releasing hormone antagonist, pituitary gonadotropin secretion is suppressed throughout stimulation to prevent a premature luteinizing hormone surge. This suppression does not instantly resolve at retrieval — the antagonist continues to block the pituitary gonadotropin-releasing hormone receptor in the early post-retrieval luteal phase, impairing the endogenous luteinizing hormone pulses that multiple corpora lutea require to sustain progesterone synthesis. Without adequate luteinizing hormone signaling, even multiple corpora lutea cannot maintain sufficient progesterone for endometrial receptivity and implantation. Exogenous progesterone supplementation bridges this gap from embryo transfer through at least the point of confirmed pregnancy, when placental progesterone begins to take over.
Question 17
A 34-year-old woman with diminished ovarian reserve undergoes in vitro fertilization using a long gonadotropin-releasing hormone agonist protocol. During stimulation she develops an unexpectedly strong follicular response with 22 mature follicles. Her physician is concerned about ovarian hyperstimulation syndrome risk and wants to use a gonadotropin-releasing hormone agonist as the ovulation trigger instead of human chorionic gonadotropin. A colleague points out that this approach is not an option in this patient. Which of the following best explains why?
Correct Answer
B — The prolonged agonist pre-treatment has downregulated and desensitized the pituitary gonadotropin-releasing hormone receptor; the pituitary can no longer generate an endogenous luteinizing hormone surge in response to an agonist dose
Rationale
The gonadotropin-releasing hormone agonist trigger works by stimulating a brief endogenous luteinizing hormone surge from the pituitary. This requires a pituitary that is fully responsive to gonadotropin-releasing hormone stimulation. In an antagonist-protocol cycle, the pituitary is suppressed by competitive receptor blockade — the blockade is rapidly reversible, and the pituitary can respond to an agonist challenge within hours. In a long gonadotropin-releasing hormone agonist protocol, the pituitary has been pre-treated with a depot agonist for 10 to 14 days, producing sustained receptor downregulation and desensitization. By the time stimulation begins, pituitary gonadotropin-releasing hormone receptors are downregulated and the gonadotroph cells are no longer responsive to further agonist stimulation. Administering an agonist trigger dose will not generate a meaningful endogenous luteinizing hormone surge from a desensitized pituitary. Human chorionic gonadotropin, which acts directly on the luteinizing hormone receptor without requiring pituitary mediation, remains the only viable trigger option in this protocol.
Question 18
A 27-year-old woman with polycystic ovary syndrome is admitted with severe ovarian hyperstimulation syndrome 5 days after fresh embryo transfer. She has tense ascites, a hematocrit of 52%, and urine output of 20 mL per hour. Her physician admits her for monitoring and starts intravenous fluids and low-molecular-weight heparin. Which of the following best explains the rationale for anticoagulation in this patient?
Correct Answer
D — Hemoconcentration from fluid redistribution into the peritoneum, combined with immobility and the hypercoagulable state of early pregnancy, substantially elevates venous thromboembolism risk, and thromboembolism is a leading preventable cause of ovarian hyperstimulation syndrome-related death
Rationale
In severe ovarian hyperstimulation syndrome, protein-rich plasma leaks from capillaries into the peritoneal cavity under the influence of supraphysiological vascular endothelial growth factor. The intravascular compartment loses both volume and oncotic pressure, producing hemoconcentration — elevated hematocrit and increased blood viscosity. This hemoconcentration raises the risk of venous and arterial thrombosis substantially. The risk is compounded by immobility from abdominal discomfort, and by the hypercoagulable state of early pregnancy if conception has occurred. Venous thromboembolism — including deep vein thrombosis and pulmonary embolism — is among the leading preventable causes of ovarian hyperstimulation syndrome-related mortality. Low-molecular-weight heparin is therefore recommended for hospitalized patients with severe ovarian hyperstimulation syndrome to reduce this thrombotic risk, and must be continued until the hemoconcentration and immobility resolve.